Prime Medicine (PRME) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$4.1M

Revenue (quarter)

$1.2M

Revenue growth (year over year)

+3.50%

Gross profit (trailing twelve months)

$4.1M

Gross margin

100.00%

Net income (trailing twelve months)

−$187.9M

Net income (quarter)

−$42.1M

Net income growth (year over year)

+19.93%

Net margin

−4613.11%

Return on equity

−373.29%

EPS (trailing twelve months)

−$1.05

Book value per share

$0.22

P/E (trailing twelve months)

—

Price to book

16.45

Debt to assets

84.02%

Payout ratio

—

Dividend yield

—

Company profile

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

• Is Prime Medicine (PRME) profitable?

  No. Prime Medicine reported a net loss of $187.9M over the trailing twelve months.

• How much revenue does Prime Medicine (PRME) make?

  Prime Medicine generated $4.1M in revenue over the trailing twelve months, up 3.50% year over year.

• How do I buy stock in Prime Medicine (PRME)?

  PRME trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.